Philips proposes new Supervisory Board appointments and reappointments, and Board of Management reappointment
Philips (NYSE: PHG) announced changes to its Supervisory Board and Board of Management. David Pyott will retire after serving three consecutive terms since 2015. The company proposed Bob White, former Executive Vice President at Medtronic, as a new Supervisory Board member and future Chair of the Quality & Regulatory Committee.
The company also proposed reappointments of Indra Nooyi and Chua Sock Koong to the Supervisory Board, citing their valuable contributions in areas including consumer products, technology, digitization, and financial expertise. Additionally, Marnix van Ginneken was proposed for reappointment to the Board of Management.
The Annual General Meeting of Shareholders will be held on May 8, 2025, where these appointments will be considered.
Philips (NYSE: PHG) ha annunciato modifiche al suo Consiglio di Sorveglianza e al Consiglio di Amministrazione. David Pyott andrà in pensione dopo aver servito tre mandati consecutivi dal 2015. L'azienda ha proposto Bob White, ex Vicepresidente Esecutivo di Medtronic, come nuovo membro del Consiglio di Sorveglianza e futuro Presidente del Comitato Qualità e Regolamentazione.
L'azienda ha anche proposto il rinnovo delle cariche di Indra Nooyi e Chua Sock Koong nel Consiglio di Sorveglianza, citando i loro preziosi contributi in settori quali prodotti di consumo, tecnologia, digitalizzazione ed esperienza finanziaria. Inoltre, Marnix van Ginneken è stato proposto per il rinnovo nel Consiglio di Amministrazione.
La Riunione Annuale degli Azionisti si terrà il 8 maggio 2025, dove queste nomine saranno considerate.
Philips (NYSE: PHG) anunció cambios en su Consejo de Supervisión y en la Junta Directiva. David Pyott se retirará tras haber servido tres mandatos consecutivos desde 2015. La empresa propuso a Bob White, ex Vicepresidente Ejecutivo de Medtronic, como nuevo miembro del Consejo de Supervisión y futuro Presidente del Comité de Calidad y Regulación.
La compañía también propuso la reelección de Indra Nooyi y Chua Sock Koong en el Consejo de Supervisión, citando sus valiosas contribuciones en áreas como productos de consumo, tecnología, digitalización y experiencia financiera. Además, se propuso la reelección de Marnix van Ginneken en la Junta Directiva.
La Junta General Anual de Accionistas se llevará a cabo el 8 de mayo de 2025, donde se considerarán estas nominaciones.
Philips (NYSE: PHG)는 감독 위원회와 경영 위원회에 대한 변화를 발표했습니다. David Pyott는 2015년부터 3연속 임기를 마치고 은퇴할 예정입니다. 회사는 Bob White를 메드트로닉의 전 부사장으로 제안하여 새로운 감독 위원회 위원으로, 품질 및 규제 위원회의 차기 의장으로 제안했습니다.
회사는 또한 Indra Nooyi와 Chua Sock Koong의 재임명을 제안하며 소비재, 기술, 디지털화 및 재무 전문성 분야에서의 그들의 귀중한 기여를 언급했습니다. 추가로, Marnix van Ginneken이 경영 위원회에 재임명될 것으로 제안되었습니다.
주주 총회는 2025년 5월 8일에 개최되며, 이들 임명이 논의될 예정입니다.
Philips (NYSE: PHG) a annoncé des changements au sein de son Conseil de Surveillance et de son Conseil d'Administration. David Pyott prendra sa retraite après avoir exercé trois mandats consécutifs depuis 2015. L'entreprise a proposé Bob White, ancien Vice-Président Exécutif chez Medtronic, comme nouveau membre du Conseil de Surveillance et futur Président du Comité Qualité et Réglementation.
L'entreprise a également proposé le renouvellement des mandats de Indra Nooyi et Chua Sock Koong au sein du Conseil de Surveillance, citant leurs précieuses contributions dans des domaines tels que les produits de consommation, la technologie, la numérisation et l'expertise financière. De plus, Marnix van Ginneken a été proposé pour le renouvellement au Conseil d'Administration.
L'Assemblée Générale annuelle des actionnaires se tiendra le 8 mai 2025, où ces nominations seront examinées.
Philips (NYSE: PHG) hat Änderungen in seinem Aufsichtsrat und Vorstand bekannt gegeben. David Pyott wird nach drei aufeinanderfolgenden Amtszeiten seit 2015 in den Ruhestand gehen. Das Unternehmen hat Bob White, ehemaligen Executive Vice President bei Medtronic, als neues Mitglied des Aufsichtsrats und zukünftigen Vorsitzenden des Qualitäts- und Regula-tionsausschusses vorgeschlagen.
Das Unternehmen hat außerdem die Wiederernennungen von Indra Nooyi und Chua Sock Koong im Aufsichtsrat vorgeschlagen, wobei ihre wertvollen Beiträge in Bereichen wie Konsumgütern, Technologie, Digitalisierung und finanzieller Expertise hervorgehoben wurden. Darüber hinaus wurde Marnix van Ginneken für die Wiederernennung im Vorstand vorgeschlagen.
Die Hauptversammlung der Aktionäre findet am 8. Mai 2025 statt, wo diese Ernennungen in Betracht gezogen werden.
- Appointment of Bob White brings extensive health technology sector expertise from leadership roles at Medtronic and GE Healthcare
- Retention of experienced board members Indra Nooyi and Chua Sock Koong maintains strategic expertise in technology, digitization, and Asian markets
- None.
- Mr David Pyott to retire from Philips’ Supervisory Board after his third consecutive term.
- Mr Bob White proposed as new member of the Supervisory Board.
- Ms Indra Nooyi and Ms Chua Sock Koong proposed for reappointment as members of the Supervisory Board.
- Mr Marnix van Ginneken proposed for reappointment as member of Philips’ Board of Management.
February 19, 2025
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced proposed Supervisory Board appointments and reappointments, and a proposed Board of Management reappointment.
Mr David Pyott (British/American, 1953) will retire from Philips’ Supervisory Board at the end of the Annual General Meeting of Shareholders 2025. Mr Pyott joined the Supervisory Board in 2015 and has served three consecutive terms. He has been Chair of the Quality & Regulatory Committee since May 2020.
The Supervisory Board will propose to the Annual General Meeting of Shareholders 2025 the appointment of Mr Bob White (American, 1962) as a new member of the Supervisory Board. Following his appointment, Mr White will succeed Mr Pyott as Chair of the Quality & Regulatory Committee.
The recommendation for this appointment is based on Mr White’s extensive expertise and experience in the health technology sector, covering the US, Europe, and Asia Pacific, and his proven track record in driving growth and fostering innovation. Until 2024, Mr White served as Executive Vice President at Medtronic, after a successful career at GE Healthcare, IBM, and other leading health technology companies.
The Supervisory Board will propose the reappointments of Ms Indra Nooyi (American, 1955) and Ms Chua Sock Koong (Singaporean, 1957) as members of the Supervisory Board.
These reappointments will be recommended given their valuable contributions to the Supervisory Board and as proven global business leaders with strong track records in areas ranging from consumer products to technology, digitization, financial and Asia. Their expertise and leadership will remain of great value as Philips further advances on its journey of improving healthcare and driving impact with care for patients, people and the planet.
The Supervisory Board will furthermore recommend the reappointment of Mr Marnix van Ginneken as a member of the Philips Board of Management, acknowledging his strong leadership, deep knowledge of Philips and his extensive international corporate governance expertise, as well as the important role he has played in the Executive Committee.
Mr Feike Sijbesma, Chairman of Philips’ Supervisory Board, said: “On behalf of the Supervisory Board and the Board of Management, I would like to express my gratitude to David Pyott for the counsel he provided over the past ten years. At the same time, we look forward to Bob White joining Philips’ Supervisory Board and becoming Chair of the Quality & Regulatory Committee. He is a recognized global business leader with deep expertise in health technology. Based on their exceptional expertise, we propose the reappointment of Indra Nooyi and Chua Sock Koong so they can continue to add valuable contributions to the Supervisory Board, for which I am grateful.
Mr Sijbesma added: “Together with my fellow members of the Supervisory Board, we recommend the reappointment of Marnix van Ginneken. I am very pleased that he remains available as a member of the Board of Management and would like to thank him for the strong leadership he has demonstrated for so many years. As a team, we continue to build on Philips’ strong foundation and brand to enable better care for more people, while delivering on the full potential of the company through Philips’ value creation strategy.”
More information about the Annual General Meeting 2025, which will be held on May 8, 2025, will be published in due course. Additional information about the Board of Management and the Supervisory Board can be found here.
For further information, please contact:
Michael Fuchs
Philips Global External Relations
Tel.: +31 61486 9261
E-mail: michael.fuchs@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries.
News about Philips can be found at www.philips.com/newscenter.
Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
Attachments
FAQ
When will David Pyott retire from Philips (PHG) Supervisory Board?
Who is proposed as the new Chair of PHG's Quality & Regulatory Committee?
Which current Supervisory Board members are proposed for reappointment at PHG?
What is Bob White's background before joining Philips (PHG)?
When will Philips (PHG) hold its Annual General Meeting in 2025?
